A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandramohan, Vidyalakshmi, Bigner, Darell D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912004/
https://www.ncbi.nlm.nih.gov/pubmed/24498557
http://dx.doi.org/10.4161/onci.26852
_version_ 1782302031940157440
author Chandramohan, Vidyalakshmi
Bigner, Darell D
author_facet Chandramohan, Vidyalakshmi
Bigner, Darell D
author_sort Chandramohan, Vidyalakshmi
collection PubMed
description Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas.
format Online
Article
Text
id pubmed-3912004
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39120042014-02-04 A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma Chandramohan, Vidyalakshmi Bigner, Darell D Oncoimmunology Author's View Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas. Landes Bioscience 2013-12-01 2013-10-22 /pmc/articles/PMC3912004/ /pubmed/24498557 http://dx.doi.org/10.4161/onci.26852 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Chandramohan, Vidyalakshmi
Bigner, Darell D
A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
title A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
title_full A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
title_fullStr A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
title_full_unstemmed A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
title_short A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
title_sort novel recombinant immunotoxin-based therapy targeting wild-type and mutant egfr improves survival in murine models of glioblastoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912004/
https://www.ncbi.nlm.nih.gov/pubmed/24498557
http://dx.doi.org/10.4161/onci.26852
work_keys_str_mv AT chandramohanvidyalakshmi anovelrecombinantimmunotoxinbasedtherapytargetingwildtypeandmutantegfrimprovessurvivalinmurinemodelsofglioblastoma
AT bignerdarelld anovelrecombinantimmunotoxinbasedtherapytargetingwildtypeandmutantegfrimprovessurvivalinmurinemodelsofglioblastoma
AT chandramohanvidyalakshmi novelrecombinantimmunotoxinbasedtherapytargetingwildtypeandmutantegfrimprovessurvivalinmurinemodelsofglioblastoma
AT bignerdarelld novelrecombinantimmunotoxinbasedtherapytargetingwildtypeandmutantegfrimprovessurvivalinmurinemodelsofglioblastoma

Ejemplares similares